---
title: "Aptorum Group Announces Merger with DiamiR Biosciences"
description: "Aptorum Group Limited (APM) has announced a merger with DiamiR Biosciences Corp., forming a wholly owned subsidiary in Delaware. This strategic move aims to enhance Aptorum's biotechnology capabilitie"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261323579.md"
published_at: "2025-10-15T21:29:39.000Z"
---

# Aptorum Group Announces Merger with DiamiR Biosciences

> Aptorum Group Limited (APM) has announced a merger with DiamiR Biosciences Corp., forming a wholly owned subsidiary in Delaware. This strategic move aims to enhance Aptorum's biotechnology capabilities, pending shareholder approval. However, Spark's analysis indicates APM stock is rated Neutral, reflecting significant financial difficulties, declining revenues, and bearish trends. The company's market cap is $11.29M, with an average trading volume of 9,958,358. Aptorum focuses on developing therapeutic projects and diagnostic technologies.

The latest announcement is out from Aptorum Group ( (APM) ).

Aptorum Group Limited announced a merger agreement with DiamiR Biosciences Corp., which was initially disclosed on July 14, 2025. The merger involves forming a wholly owned subsidiary in Delaware, which will merge with DiamiR, making it a wholly owned subsidiary of Aptorum. This strategic move aims to enhance Aptorum’s capabilities in the biotechnology field, potentially impacting its market positioning and stakeholder interests. The merger is contingent upon shareholder approval and other conditions outlined in the agreement.

**Spark’s Take on APM Stock**

According to Spark, TipRanks’ AI Analyst, APM is a Neutral.

Aptorum Group’s overall stock score of 41 reflects significant financial difficulties, with declining revenues and persistent losses as primary concerns. Technical analysis indicates bearish trends, and valuation metrics suggest the stock may be overvalued. The lack of earnings call and corporate events data leaves these areas unassessed.

To see Spark’s full report on APM stock, click here.

**More about Aptorum Group**

Aptorum Group Limited is a company based in the Cayman Islands with its principal executive office in London, United Kingdom. It operates in the biotechnology sector, focusing on developing and commercializing therapeutic projects and diagnostic technologies.

**Average Trading Volume:** 9,958,358

**Technical Sentiment Signal:** Hold

**Current Market Cap:** $11.29M

For a thorough assessment of APM stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [APM.US - Aptorum](https://longbridge.com/en/quote/APM.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Aptorum Group Announces Strategic Merger with DiamiR Biosciences | Aptorum Group Limited has announced a strategic merger with DiamiR Biosciences Corp. to enhance its operations. The merg | [Link](https://longbridge.com/en/news/260333819.md) |
| Aptorum Group Issues Amended SEC Filing on DiamiR Merger | Aptorum Group Ltd. has amended its SEC filing regarding its merger with DiamiR Biosciences Corp., providing additional d | [Link](https://longbridge.com/en/news/268802337.md) |
| Sweden's Medivir posts Q4 revenue of SEK 5.5 mln | Swedish biotech firm Medivir reported Q4 revenue of SEK 5.5 million and entered an exclusive license agreement with Bios | [Link](https://longbridge.com/en/news/276206336.md) |
| Sweden's Cantargia 2025 sales rise but miss analyst expectations | Sweden's Cantargia reported 2025 net sales of SEK 316.7 million, falling short of analyst expectations of SEK 321.4 mill | [Link](https://longbridge.com/en/news/276415839.md) |
| BUZZ-Compass Pathways climbs premarket after $150 mln equity raise | Compass Pathwaysshares rose 2.8% premarket to $8.69 following a $150 million equity raise. The UK-based biotech priced 1 | [Link](https://longbridge.com/en/news/276332888.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.